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& The DR-70
1 (FDP) test was the first cancer test cleared by USFDA for monitoring colorectal
cancer (CRC) since Carcinoembryonic Antigen (CEA) in 1982. Conservatively, 50% of
biopsy-positive CRC patients have negative CEA values. DR-70 and CEA values were compared
for 113 CRC monitoring patients. Total concordance rates for DR-70 and CEA were 0.665 and
0.686, respectively. CRC patient pairs were grouped based on their CEA value to deduce DR-700s
effectiveness at monitoring patients with low CEA values. DR-70 had 12% to 100% greater posi-
tive concordance rates than CEA in this group. DR-70 is a welcome new option for CRC patients.
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INTRODUCTION
Awareness of theimportance ofCRC screening
[1] and earlytreatment has
risen,
[2] but CRC is presently still a significant health concern in the United
States.
[3] In 2007, the Surveillance, Epidemiology and End Results (SEER)
program estimated there were 153,760 new colorectal cancer patients
[4] with
a five year survival prediction of 50%. CRC accounts for approximately 10.6%
of all new cancer cases and approximately 10% of all cancer deaths in the
United States.
[5] Colorectal cancer (CRC) remains the second leading cause
of cancer death in the United States,
[5] despite a reported decrease in color-
ectal cancer mortality over the past forty years. This decreased rate is related
to increased screening, intervention, and monitoring programs.
Monitoring programs have emerged as an important tool in enhancing
survival in post-operative CRC patients.
[6] For CRC, approximately half
of all patients treated will experience disease recurrence.
[7] Curative
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modest decrease in CRC mortality (approximately 10–15%).
[8–10] However,
in order to enhance the survival benefit of CRC monitoring programs,
‘‘the availability of sensitive and specific tests to identify recurrences at a
treatable stage’’ needs improvement.
[6]
The AMDL-ELISA DR-70 (FDP) test (AMDL Diagnostics, Inc., Tustin,
CA) is the first new in vitro diagnostic cancer test to be cleared by the
US FDA for monitoring colorectal cancer (CRC) since January 14, 1982
when Carcinoembryonic Antigen (CEA) was approved. CEA has been in
routine usage for many years as a blood test for monitoring CEA, but it also
has well known limitations that are related to the nature of the tumor
marker.
[6] CEA has been characterized as an oncofetal marker, which
implies that it is only present during cancer progression or normal
embryogenesis. Evidence exists that contradicts its classification as a pure
oncofetal marker; as there are reports of this antigen’s presence in healthy
organs and its elevation due to benign conditions that affect the liver,
[11–14]
lungs,
[15] and the gastrointestinal system.
[16] Also, CEA is not a good target
for a blood test because CEA is normally firmly attached to cancer cells
due to its role as an adhesion molecule.
[15] In contrast, the DR-70 (FDP)
antigen is freely diffusible in the blood.
For many CRC patients with biopsy confirmed cancer, CEA levels are
not measurable above the physiological background. Data was taken
directly from three independent studies
[17–19] and presented directly in
Table 1 below to assess the need for an additional CRC monitoring tool.
Approximately 50% of all CRC patients with low CEA values can not use
the CEA test to monitor their cancer because their CEA levels fall below
the manufacturer’s defined physiological background level. In the table
below, CEA Low Responders is the term given for biopsy positive cancer
patients with low CEA values. All of the numbers in the table have been
published in the referenced papers.
The DR-70 test measures both Fibrin and Fibrinogen Degradation
Products (referred to collectively as FDP in this paper) in human serum
samples. Measuring multiple FDP species prevents the DR-70 (FDP) immu-
noassay from underestimating the cancer-related levels of FDP.
[20] Refer to
TABLE 1 Literature Based Definition of the % of CRC Patients Not Able to Use CEA
Study Year
Number
of Patients
% Below CEA Cut-Off by Duke’s Stage Overall %
CEA Low
Responders AB C D
17Landenson et al. 1980 203 97 75 55 35 58
18Wang, J.Y. et al. 1994 318 100 68 52 21 NA
19Wang, W.S. et al. 2000 218 75 61 29 NA 53
132 A. L. Small-Howard and H. HarrisFigure 1 for a schematic describing how the DR-70 (FDP) assay measures
FDP generated from all of the major cancer induced FDP production path-
ways. Researchers have established a strong link between increased FDP
levels and cancer.
[20–22] This strong link is based on multiple factors includ-
ing: a cancer-caused redirection of the coagulation cascade and a cancer-
related increase in proteolysis within tumors as they grow and metastasize.
Because the DR-70 test uses a different tumor marker than the CEA test,
physicians have an additional blood test for monitoring CRC patients that
may be superior to CEA for many of their patients with low CEA values. The
purpose of this study is to determine if DR-70 is effective at monitoring
CRC patients with low CEA levels.
EXPERIMENTAL
Description of the Clinical Samples
The samples for the serial monitoring study were retrospective banked
samples that were collected blindly and without bias to include all patients
FIGURE 1 Cancer Elevates FDP Levels Through Two Pathways: Coagulation and Fibrinolysis. The
AMDL-ELISA DR-70
1 (FDP) test measures the FDP produced by multiple pathways, unlike other
FDP assays which only measure one pathway or one pathway product. Researchers have established that
cancer causes elevated levels of both urokinase-type plasminogen activator (u-PA)
[23–25] and tissue
factor (TF).
[26–28] Both the u-PA and TF pathways effect the production of FDP in cancer cells. The
u-PA pathway (1A and 1B) activates plasmin by transforming plasminogen, the inactive precursor of
plasmin, into functional plasmin.
[23–25] The TF pathway (2) alters the extrinsic coagulation system caus-
ing an activation of thrombin.
[26–29] Thrombin (3) converts Fibrinogen to Fibrin.
[30] The type of FDP
produced will be different depending upon which of the two substrates is digested by plasmin. When
fibrinogen is the substrate for plasmin (4), fragments D and E are the end products with fragments
X and Y as intermediate products in this digestion. When fibrin is the substrate of plasmin (5), D-dimer
is the end product. As a result of either pathway (4) or (5), cancer will cause an elevation in FDP levels
as measured by the DR-70 (FDP). Tests that measure only one of the individual FDP species, i.e.,
D-dimer tests, will miss up to half of the FDP generated as a result of cancer physiology. (Figure is
provided in color online.)
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The serial monitoring samples for this study were obtained from two retro-
spective sample banks. Forty-eight serial sets were obtained from Geffen
Cancer Center in Vero Beach, FL and sixty-four serial sets were from the
serum banks at MD Anderson Cancer Center in Houston, TX. Institutional
Review Board Approval for use of the samples and informed consent were
available for each patient sample set.
Clinical information detailing the status of each patient’s disease was
collected at the time of each sample draw. The clinical diagnoses included
Duke’s Stage, grade and type (colon or rectal cancer). None of the patients
had a history of malignancy within the past five years of the initial sample
draw other than colorectal cancer. A breakdown of the patient series is pre-
sented in Table 2. The average number of observations per patient is 4.0.
Of the original 113 patients, one had to be dropped from further analy-
sis due to incomplete clinical records. The 112 evaluable subjects in this
CRC monitoring cohort consisted of 44 males and 68 females. The average
age of the male patients was 65 while female patients averaged 62 years. The
overall average age was 63 years. There was no significant difference
between the average age of the males and the females in this cohort based
on a student’s t-test analysis for the determination of variances [t¼1.41,
p¼0.163 (unequal variances)].
TABLE 2 Patient Observation Series
Number
of Samples
in Series
Number
of Observation
Pairs in Series
Total Number
of Series with
that Number
of Pairs
Percent of the
Total Samples
Cumulative
Percent
of Samples
2 1 1 0.9 0.9
3 2 38 33.9 34.8
4 3 48 42.9 77.7
5 4 18 16.1 93.8
6 5 3 2.7 96.5
7 6 3 2.7 99.2
8 7 1 0.9 100.0
TABLE 3 Ethnic Distribution
Ethnic Background Frequency Percent
African American 7 6.3
Asian 2 1.8
Caucasian 99 88.4
Hispanic 4 3.6
Total 112 100.0
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mately 88% percent of the cohort was Caucasian; approximately 6% of
African-American background; approximately 4% of Hispanic descent;
and approximately 2% of Asian decent.
Table 4 presents the Dukes stage of the disease at time of diagnosis for
111 of the 112 evaluable serial patients. One patient’s chart did not contain
information related to the stage at time of diagnosis.
Table 5 demonstrates the relationship between Dukes Stage at diagnosis
and the presence of metastases. As the Stage of the disease progressed, the
percentage of patients with metastases increased.
Statistical Analysis Plan for Association Between DR-70
1
(FDP)/AIA-Pack
TM CEA and Disease Status
The initial objective of this analysis is to determine the overall positive,
negative and total concordance values of the DR-70 (FDP) and CEA
assays.
[31] Then, the CRC patients will be grouped based on their CEA values
to evaluate the effectiveness of the DR-70
1 (FDP) assay at monitoring CRC
patients with low CEA values; defined as a CEA value of 30 or below.
TABLE 4 Stage of Cancer at Time of Diagnosis
Dukes Stage
at Diagnosis Frequency Percent
Cumulative
Percent
A 5 4.5 4.5
B 18 16.2 20.7
C 39 35.1 55.9
D 49 44.1 100.0
Total 111 100.0
TABLE 5 Distribution of Metastases by Stage at Diagnosis
Dukes Stage
Known Metastases at Time of Diagnosis
Total Yes No
A0 5 5
0.0% 100.0% 100.0%
B 3 15 18
16.7% 83.3% 100.0%
C2 9 1 0 3 9
74.4% 25.6% 100.0%
D4 9 0 4 9
100.0% 0.0% 100.0%
Total 81 30 111
73.0% 27.0% 100.0%
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Serial samples were taken from 112 colon cancer patients resulting in a
total of 445 paired observations in which a DR-70 (FDP) reading and a deter-
mination of disease progression were obtained. In total, there were also 445
paired observations in which an AIA-Pack
TM CEA Assay reading and a deter-
mination of disease progression were obtained. The sequential draws cov-
ered an average longitudinal period of at least nine months. Progression
of the DR-70 (FDP) value or AIA-Pack CEA Assay value in the serial monitor-
ing set was evaluated as a percentage change between the current and pre-
vious readings (Y). The minimum percentage to specify disease progression
in either assay was determined to be 15%, as will be described in detail later.
Clinical disease progression (D) was determined by the Subject’s physician
based on their office procedures and clinical laboratory based analyses that
were the standard of care during the time of the monitoring period.
Monitoring Cases for Response to Therapy
Subjects in the serial monitoring cohort were followed after surgery and
or after various types of therapy including chemotherapy and radiation
therapy. The response to therapy was evaluated using information provided
in the records by the clinicians based on the results of clinical examinations
and imaging results (i.e., bone scans, CT scans, magnetic resonance ima-
ging studies, radiography, or ultrasound).
Response to therapy is defined as follows:
. Complete response (CR) or no evidence of disease (NED): The complete
disappearance of all clinical and image-measurable disease as evidenced
by the clinical exam and imaging or other diagnostic modalities as
ordered by the physician.
. Partial Response (PR): In patients with metastases at the time of the orig-
inal draw, a noticeable reduction in the size of primary metastatic lesions
or bone metastases demonstrating at least stabilization as observed on
the bone scan.
. Stable Disease (SD): No significant change in the size of primary meta-
static lesions or no noticeable increase in the size of primary lesions or no
new lesions as evidenced by the clinical exam and imaging or other
diagnostic modalities as ordered by the physician.
. Progressive Disease (PD): Clinical or imaging results that clearly indicate
the presence of lesions not seen on previous examinations or a signifi-
cant increase in the size of primary or metastatic lesions.
Definition of Outcome Measure
The outcome measure for this analysis is the determination of
progression of disease from time point i (clinical visit i, i¼1t on 1) to
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the number of clinical visits for which samples are collected from a Subject
after diagnosis of colorectal cancer and prior to death, loss to follow up or
remission of disease.
Let Dij represent the variable disease progression as measured above
and allow Dij to have the values
Dij ¼
1 if there is progression of disease from visit i to visit j:
0 if there is no progression of disease, the disease is either
stable or responding to therapy, from visit i to visit j:
Determining Values of D
Disease progression from visit i to visit j will be determined by the
Subject’s physician based on any or all of the following:
. Examination of the subject for clinical signs and symptoms, including the
results of laboratory tests that are current standard of care for the assess-
ment of colorectal cancer disease status.
. Examination of radiographic findings (imaging) that can be used for the
assessment of colorectal cancer disease status. Radiographic findings
include results from CAT scans, PET scans, MRI and X-Ray images.
Determination of Clinical Significance in Marker Value Change
To ensure that the change between the values of the test device over a
time interval could not be attributed to assay variation, a 15% increase from
the previous visit was determined to be the most appropriate threshold for
significant % change for the determination of disease progression in the
DR-70 (FDP) assay. The coefficient of variation (CV) used in the calculation
for significant % change was based on an imprecision study following regu-
latory guidelines. In that precision study, the total CV over all runs, days,
and intra-assay was computed for each control specimen analyzed. The
highest CV values were observed for specimens with a low concentration
of (0.21–0.42mg=mL); however, in a study of cancer progression, such as
the one being reported here, such samples constituted less than 5% of
the measurements. Over 80% of the measurements had concentrations of
0.6mg=mL or higher where the CV is lower. Therefore the CV values for
the lower concentrations will not be used to determine the significant %
change. If the CV values for the highest laboratory specimens with concen-
tration of 1.31 (CV¼7.85) or 4.11 (CV¼7.14) mg=mL are averaged, the
mean is 7.495%. The CV is given by the following formula.
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r
  x x
whichisthestandarddeviationdividedbythemean.Theproportiondifference
between two successive measurements is given by the following formula.
p ¼
x2   x1
x1
where p is the proportion difference from the previous measurement. Normal
theory would suggest that 97.5% of the measurements are within the range of
the following expression.
  x x þ 1:96r
Using the expression for CV, we can solve for r a n do b t a i na ne x p r e s s i o nt h a t
can be used to define the difference between successive measurements.
  x x þ 1:96 
CV     x x
100
Assuming that the previous measurement was a mean at that time, less than
2.5% of the time, by chance, will the following expression hold.
x2 > x1 þ
1:96 CV  x1
100
Algebraically rearranging this expression we get the following.
x2   x1
x1
>
1:96 CV
100
Alternatively the following can be used.
x2
x1
> 1 þ
1:96 CV
100
Usingthe value of7.495 on the previouspage,thisexpression indicates thatthe
proportion of difference must be greater than 7.495*1.96=100¼0.1469. For
simplicity, this cut off value has been rounded up to 0.15 or 15% or the ratio
shouldexceed1.15.Thusifalatervisithasavaluethatisgreaterthan15%higher
than the previous value, it will be considered evidence of disease progression.
A1 5 % increase from the previous visit was also determined as the most
appropriate threshold for significant % change for the determination
of disease progression using the AIA-Pack
TM CEA Assay from TOSOS
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the AIA-Pack
TM CEA Assay product insert.
Definition of Significance in Marker Value Change
Let d equal the significant change in marker value for either assay, which
has been determined at 15% for either assay, as described above. Let xi be the
value of the test device obtained from the assay of a blood sample drawn from
the Subject at visit i and xj be the value of the test device obtained from the
assay of a blood sample drawn from the Subject at visit j.
Define Yij as
Yij ¼
1i f ðxj   xiÞ d   xi
0 otherwise
Determining the Association Between D and Y
With Dij and Yij defined above for either assay, a 2 2 contingency table
can be constructed for the analysis of this data. The contingency table has
the format of Table 6. In this table the variable a represents the number of
(Yij, Dij) pairs that have the value of 1 for both Yij and Dij. The variable b
represents the number of (Yij, Dij) pairs that have the value 1 for Yij and
0 for Dij. The variable c represents the number of (Yij, Dij) pairs that have
the value 0 for Yij and 1 for Dij. Lastly variable d represents the number of
(Yij, Dij) pairs that have the value of 0 for both Yij and Dij. The accrued
values of a, b, c, and d are determined over all serial interval values of Yij
and Dij. The sum of a, b, c and d is the total number of all (Yij, Dij) pairs
for all Subjects. This sum is designated N in Table 6.
From Table 6, sensitivity and specificity are computed as follows:
Specificity: 100 d=ðb þ dÞ
Sensitivity: 100 a=ða þ cÞ
TABLE 6 Model Contingency Table for D and Y
Dij¼1 Disease
Progression
Dij¼0
No Progression Total
Yij¼1 Significant increase in
tumor marker as measured by
assay
ab a þb
Yij¼0 No Significant increase in
tumor marker as measured by
assay
cd c þd
Total aþcb þdN
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Positive Concordance ðCþÞ ¼ a=ða þ cÞ
Negative Concordance ðC Þ ¼ d=ðb þ dÞ
Total Concordance ðCÞ¼ð a þ dÞ=N
Justification of Sample Size
Given the above assumptions and calculations, the minimum sample
size for this study was determined to be 70 subjects with an average of 3
draws each.
[31] The samples are retrospective banked samples collected
blindly and unbiased. Out of a total of 445 evaluable observations, there
were 112 evaluable patient serial sets with an average of 4 draws each.
RESULTS
General Effectiveness of DR-70 (FDP) or CEA for CRC
Monitoring
The clinical trial results were tabulated, as described above. The results
for the DR-70 (FDP) test immediately follow in Table 7 and the results for
CEA are found in Table 8. In addition, the following interpretations are
provided: Positive Concordance (Cþ), Negative Concordance (C ), Total
Concordance (C), Sensitivity, and Specificity.
Based on these data the concordances for the DR-70 (FDP) vs. Clinical
Disease Status are:
CþðPositive concordanceÞ¼0:652;
C ðNegative concordanceÞ¼0:673 and
C ðTotal overall concordanceÞ¼0:665:
In estimating the specificity and sensitivity of the DR-70 (FDP) test, using
a significant % change value of 15% or a ratio value of 1.15 or higher,
TABLE 7 Clinical Disease Status vs. AMDL-ELISA DR-70 (FDP)
DR-70 (FDP)
Clinical Disease Status
Total Progression No Progression
Significant increase (>15%) 88 65 153
No significant increase (<15%) 47 134 181
Total 135 199 334
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tivity of 65%.
Based on these data the concordances for the TOSOH AIA-PACK CEA
vs. Clinical Disease Status are:
CþðPositive concordanceÞ¼0:739;
C ðNegative concordanceÞ¼0:653 and
C ðTotal overall concordanceÞ¼0:686:
In estimating the specificity and sensitivity of the CEA test, using a signifi-
cant % change value of 15% or a ratio value of 1.15 or higher, the estimated
specificity was determined as 73% with an estimated sensitivity of 65%.
TABLE 8 Clinical Disease Status vs. the TOSOH AIA-PACK CEA
CEA
Clinical Disease Status
Total Progression No Progression
Significant Increase (>15%) 99 69 168
No Significant Increase (<15%) 35 130 166
Total 135 199 334
FIGURE 2 Positive Concordance for DR-70 or CEA Grouped by CEA values. Positive progression
patient sample pairs were grouped in ascending order based on the CEA value. The % Concordance
for DR-70 relative to the clinical findings was graphed in blue for each group. The % Concordance
for CEA relative to the clinical findings was graphed in red for each group. Forty-six (46) of the 135
total positive progression patient pair values fell in the groups containing CEA values of 30 or less.
(Figure is provided in color online.)
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Low CEA Values
After grouping the CRC patients’ sample pairs in ascending order
based on their CEA values, the following relationships were revealed.
Positive concordance values of CRC patients measured with DR-70 or
CEA in patient groups relative to their CEA values are provided in
Figure 2. Negative concordances of CRC patients measured with DR-70
or CEA in groups relative to their CEA values are provided in Figure 3.
In Figure 2, DR-70 had between 12% and 100% greater positive
concordance rates than CEA for CRC monitoring patients with low CEA
values. In contrast, the negative concordance values of DR-70 and CEA
showed less than 10% difference for all CRC patient groups in the trial,
as depicted in Figure 3.
DISCUSSION
Overall, the results from this trial support the assertion that the
AMDL-DR-70 (FDP) test is as good at monitoring CRC patients as CEA.
FIGURE 3 Negative Concordance for DR-70 or CEA Grouped by CEA values. Negative progression
patient sample pairs were grouped in ascending order based on the CEA value. The % Concordance
for DR-70 relative to the clinical findings was graphed in blue for each group. The % Concordance
for CEA relative to the clinical findings was graphed in red for each group. There were a total of 199
negative progression patient pair values. (Figure is provided in color online.)
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ance values for DR-70 and CEA are 0.665 and 0.686, respectively. The total
concordance values for DR-70 and CEA differed by only 3.2% in this clinical
trial.
In addition, Figure 2 suggests that DR-70 is more effective at monitor-
ing patients whose CEA values are 30 or less. Forty-six (46) of 135 positive
progression patient pair values fell in the groups containing CEA values of
30 or less. In this group, DR-70 had between 12% and 100% greater positive
concordance rates than CEA for CRC monitoring patients. The negative
concordance rates were about the same for both assays across all groups
when ordered by the CEA value of the patient. The difference between
the negative concordance rates of these assays was less than 10% for all
patient groups relative to their CEA values. Additional trials are planned
to examine this same sub-group to verify the value of the test for patients
with low CEA values.
The results of this trial suggest that DR-70 could have a positive impact
on mortality that is associated with CRC recurrence. All of the patients in
the reported trial were either post-surgery with no adjuvant therapy or post-
therapy, as was described in the methods section. This holds clinical signifi-
cance because disease progression in these patients would be described as
disease recurrence. As reported in the introduction, approximately half of
all CRC patients treated will experience disease recurrence. An additional
and improved tool for the monitoring of disease recurrence could
profoundly impact the mortality rate that is associated with CRC
recurrence. Future studies could assess the impact of the DR-70 test on
clinical outcomes in a longer term, prospective trial.
FDP has been shown to be valuable as a tumor marker in a number of
different cancers.
[32–43] FDP levels correlate with cancer occurrence, stage,
progression and prognosis. Among these studies, the DR-70 (FDP) assay
was used to detect FDP levels in 7,839 patients and the DR-70 (FDP) assay
results consistently correlated with either the positive detection or positive
progression of a variety of cancers.
Researchers have established a strong link between increased FDP levels
and cancer which is based on multiple factors including: a cancer-caused
redirection of the coagulation cascade
[44–49] and a cancer-related increase
in proteolysis within tumors as they grow
[50,51] and metastasize.
[52–56] Clini-
cal studies reveal that measuring FDP levels, either with the DR-70 (FDP)
test or with other related tests, has significant diagnostic value for a variety
of cancers. These studies demonstrate that FDP levels correlate with the
cancer stage
[41–43,57–60] and with the cancer progression,
[41,59,61] as quanti-
fied by the number of lymph node metastases. Clinical research efforts have
shown that pretreatment measurements of FDP levels have prognostic
significance for post-treatment survival.
[33,60,62–66] In addition to survival
Advantages of DR-70 over CEA for CRC Monitoring 143prognoses, pretreatment FDP values may be used to indicate when adjuvant
systemic treatments are required for surgical Subjects.
[64,66]
Cancer is a disease that is characterized by disregulation at the cellular
level. As cancer progresses, the cellular disregulation spreads to the systems
level. The coagulation system is one of the first systems affected by
cancer-related processes. As referenced in Figure 1, the coagulation
pathway may be inappropriately activated in cancer patients either by the
activation of the coagulation pathway alone, the fibrinolysis pathway alone,
or both pathways simultaneously. Coagulation may be increased due to
elevated levels of tissue factor (TF),
[62,67] which acts through the extrinsic
coagulation system. Alternatively, the fibrinolysis pathway may be mis-
takenly activated in cancer patients through elevations in the levels of
urokinase-type plasminogen activator (u-PA)
[44] that activates the protease
plasmin. Disregulation of the coagulation system has important adverse
affects on cancer patients because the coagulation system plays dual roles
in homeostasis and immunity. As the cancer-related disregulation of the
coagulation system increases, these clots can lead to heart attack, stroke,
or pulmonary embolism. Other FDP-related tests have been helpful in
predicting survival outcome based on the often fatal consequences of blood
clots in cancer patients.
[59,62,67] As the utility of the DR-70 (FDP) assay
becomes more widely known, DR-70 should be adapted to help patients
with a variety of cancers in different clinical settings.
CONCLUSIONS
The DR-70 test appears to have additional benefits in monitoring CRC
patients with low CEA values. DR-70 had between a 12% and a 100% greater
positive concordance rate than CEA for CRC monitoring patients with low
CEA values. Given that 50% is a conservative estimate of CRC patients with
low CEA values, physicians and patients could significantly benefit from this
new option for monitoring CRC cancer.
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